# Aktis Oncology, Inc. (AKTS)

> Source: Nexqual · https://nexqual.com/AKTS · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Aktis Oncology, Inc. (AKTS), nexqual.com/AKTS" · informational, not investment advice.

**Price:** USD 16.85 (+0.18% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 16.82 · day 16.61–17.33 · 52w 14.72–34.19 · market cap $937M · NMS

## Key facts
- 1 of 80 tracked superinvestors hold AKTS (13F, Q2 2026): 1 new, 0 added, 0 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 5 Form 4 filings, $3.2M; 4 not under a Rule 10b5-1 plan ($3.0M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.90 on a 1–5 scale) (10 analysts), mean target USD 35.88 (range 33–40).
- Total return with dividends: 1Y -24.9% vs S&P 500 +14.8%; 5Y -24.8% vs S&P 500 +79.1%.
- Next earnings: 2026-11-12 (date not yet confirmed by the company), EPS estimate USD -0.45, revenue estimate $2.5M. All companies reporting that day: https://nexqual.com/earnings/2026-11-12
- Dividend: AKTS paid no cash dividend in the last five years.
- Short interest: 26.68% of float (as of 2026-10-15), 8.4 days to cover.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 97.0x · P/B 1.9x · FCF yield -9.07% · Earnings yield -8.06%

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold AKTS. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Polen Capital | Polen Capital Management | 0.02% | $2.0M | New position |

## Insider sales (SEC Form 4, open-market, last ~7 months)
1 of 5 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-23 | Czibere Akos | Chief Medical Officer | 12,500 | $259K | 100% | Yes (adopted June 24, 2026) | Too little history (no open-market trades in 2023–2025) |
| 2026-07-20 | Herrmann Ken | Director | 4,856 | $119K | 100% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-07-17 | Herrmann Ken | Director | 3,065 | $77K | 100% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-07-08 | Ron-Bigger Shulamit | Chief Operating Officer | 50,000 | $1.4M | 100% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-07-08 | Czibere Akos | Chief Medical Officer | 50,000 | $1.4M | 100% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Buy (mean 1.90 on a 1–5 scale), 10 analysts; mean target USD 35.88 (low 33, high 40).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-02 | Wedbush | Reiterated | Outperform | $35 |
| 2026-09-09 | Oppenheimer | Initiated | Outperform | $40 |
| 2026-08-19 | Wedbush | Initiated | Outperform | $35 |
| 2026-08-19 | BMO Capital | Initiated | Outperform | $37 |
| 2026-07-14 | JP Morgan | Target raised | Overweight | $30 → $33 |

## Total return (dividends reinvested)
|  | 1Y (from 2026-01-09) | 5Y (from 2026-01-05) |
|---|---|---|
| Total return | -24.9% | -24.8% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | — | — |
| Volatility (annualized) | 67.7% | 67.8% |
| Max drawdown | -53.3% (Jun 2026→Oct 2026) | -52.6% (Jun 2026→Oct 2026) |

## Dividends
AKTS paid no cash dividend in the last five years.

## Short interest
4,313,744 shares sold short, 26.68% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 3,252,475 shares (+32.6%). Days to cover: 8.4 (short shares ÷ average daily volume).

## Peers (Biotechnology)
LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · RYTM (Rhythm Pharmaceuticals, Inc.) USD 93.07 +1.20% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/AKTS · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Company outlook (8-K filed 2026-08-13)

- "Roden added, "In the second half of 2026, we expect to initiate the Phase 1b trial with AKY-2519 in B7-H3 expressing solid tumors, representing our third Phase 1b trial."
- "The Company's cash, cash equivalents, and marketable securities as of June 30, 2026, are expected to fund the Company's operating plan into 2029. • Collaboration revenue: Collaboration revenue was $3.4 million for the quarter ended June 30, 2026, compared to $1.6 million for the comparable prior-year period."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.45 | $-0.46 | $0.00 | $2.5M | 7 |
| Next quarter (ends 2026-12-31) | $-0.46 | $-0.34 | −$0.11 | $2.1M | 6 |
| Current fiscal year (ends 2026-12-31) | $-1.68 | $-1.62 | −$0.06 | $10.6M | 8 |
| Next fiscal year (ends 2027-12-31) | $-2.14 | $-1.97 | −$0.17 | $10.3M | 8 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.44 | −$0.43 | Miss −2.3% | — |
| — | Quarter ended Mar 31, 2026 | −$0.38 | −$0.33 | Miss −15.2% | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-08-13 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/2035832/000119312526349144/0001193125-26-349144-index.htm |
| 2026-08-13 | 8-K | Quarterly results | https://www.sec.gov/Archives/edgar/data/2035832/000119312526349133/0001193125-26-349133-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.